STAT

Kale crackers and hibiscus tea: My five days on a ‘fasting diet’

I tried the five-day ProLon diet, an ultra-low-calorie regimen meant to trick your body into thinking you're fasting. It wasn't as bad as I'd feared.

LOS ANGELES — The box is lovely, sleek and white. But it’s so small.

I’ve decided to try the ProLon diet — five days of “mimicking fasting” that is supposed to help me lose weight, trim belly fat, drop my cholesterol and glucose levels into healthier zones, and even slow aging. I’ve been researching the science behind fasting — check out my full story on that topic here — so I’m excited to try it myself.

But the box is so small. Not much larger than a shoebox, it contains all the food and drink, other than water, that I’ll get for five days. I sift through the futuristic-looking — and tiny — packets of olives and freeze-dried soups, kale chips, and nut bars. I love food so much. I’m a little bit worried.

The diet consists of an ultra-low-calorie blend of proteins, carbohydrates, fats, and nutrients that’s meant to trick the body into thinking it is fasting, but with less discomfort or risk than a true water-only fast. That’s according to its inventor, biochemist Valter Longo, the director of the Longevity Institute at the University of Southern California.

He’s launched a company, L-Nutra, to market the diet; it’s sold for $300 per

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

Related Books & Audiobooks